期刊文献+

血浆tHcy对评估非小细胞肺癌化疗效果及其活动状态价值的研究 被引量:1

The role of tHcy expressions in evaluating the effects of chemotherapy in treating non-small cell lung cancer and tracking the tumor's activity
下载PDF
导出
摘要 目的探讨血浆总同型半胱氨酸(total homecysteine,tHcy)表达水平对评估晚期非小细胞肺癌(non-small celllung cancer,NSCLC)化疗效果及肿瘤活动状态的价值。方法采用前瞻性对照研究方法,分析80例晚期非小细胞肺癌化疗前后有效控制、进展、有效控制后复发时tHcy的变化,进而评价tHcy与化疗效果及肿瘤活动状态的关系。结果 80例晚期非小细胞肺癌患者化疗1~2周期后,56例得到有效控制,其tHcy由(16.75±4.83)μmol.L-1降至(10.92±3.26)μmol.L-1。在随访过程中34例复发,其tHcy由(12.57±3.02)μmol.L-1升高至(19.23±3.58)μmol.L-1。化疗无效进展者24例,其tHcy由(15.82±4.75)μmol.L-1升高至(20.32±4.50)μmol.L-1。三组差异均有统计学意义(P<0.05)。结论 tHcy对评价晚期NSCLC化疗效果及肿瘤活动状态有重要价值。 Objective To develop a scientific method for evaluating the effects of chemotherapy in treating advanced non-small cell lung cancer(NSCLC) and tracking the activity of the tumor.Method 'Prospective case-control study' is employed to analyze the changes of tHcy before and after the effective control,in the progress,and in the recurrence after effective control of 80 cases of advanced NSCLC,and evaluate the relationship between tHcy and the effect of chemotherapy and the activity of tumor.Results After the first or second cycle of chemotherapy,56 cases among the 80 advanced NSCLC have been effectively controlled.Their tHcy decreased from(16.75± 4.83)μmol·L-1 to(10.92±3.26)μmol·L-1.34 cases of the follow-up recurred,and their tHcy rose from(12.57±3.02)μmol·L-1 to(19.23±3.58)μmol·L-1.24 cases of chemotherapy were invalid,and their tHcy rose from(15.82±4.75)μmol·L-1 to(20.32±4.50)μmol·L-1.The differences among these three groups are statistically significant(P0.05).Conclusion tHcy can be an efficient benchmark in evaluating the effects of the advanced NSCLC chemotherapy and the activity of the tumor.
出处 《健康研究》 CAS 2013年第4期280-282,共3页 Health Research
关键词 非小细胞肺癌 总同型半胱氨酸 化疗 肿瘤标志物 NSCLC chemotherapy tHcy tumor marker
  • 相关文献

参考文献10

  • 1Jemal A,Center MM,Desantis C. Global patterns of cancer incidence and mortality rates and trends[J].Cancer Epidemiology Biomarkers and Prevention,2010,(08):1893-1907.
  • 2Peter G. Staging manual in thoracic onocology[M].Orange Park,LL,USA:Editorial Rx Press,2009.
  • 3Ohe Y,Ohashi Y,Kubota K. Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan[J].Annals of Oncology,2007,(02):317-323.doi:10.1093/annonc/mdl377.
  • 4Winton T,Livingston R,Johnson D. Vinorelbine plus cisplatin vs.observation in resected non-small-cell lung cancer[J].New England Journal of Medicine,2005,(25):2589-2597.
  • 5Therasse P,Arbuck SG,Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada[J].Journal of the National Cancer Institute,2000,(03):205-216.doi:10.1093/jnci/92.3.205.
  • 6Sun CF,Haven TR,Wu TI. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death:a potential new tumor marker[J].Clinica Chimica Acta,2002,(1-2):55-62.
  • 7Ozkan Y,Yardim-Akaydin S,Firat H. Usefulness of homocysteine as a cancer marker:totaI thiol compounds and folate levels in untreated lung cancer patients[J].Anticancer Research,2007,(02):1185-1189.
  • 8Sirachainan N,Sasanakul W,Visudtibhan A. The effect of polymorphisms of MTHFR C677T,A1298C,MS A2756G and CBS 844ins68bp on plasma total homocysteine level and the risk of ischemic stroke in Thai children[J].Thrombosis Research,2008,(01):33-37.
  • 9Wu LL,Wu JT. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker[J].Clinica Chimica Acta,2002,(1-2):21-28.
  • 10Kao SC,Phan VH,Clarke SJ. Predictive markers for haematological toxicity of pemetrexed[J].Current Drug Targets,2010,(01):48-57.

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部